INyX, Inc. is a developer and manufacturer of specialised drug delivery pharmaceutical products. INyX’s expertise is focused on niche aerosol products and technologies for the treatment of respiratory, allergy, dermatological and topical conditions.
INyX's client base is comprised of blue-chip ethical pharmaceutical companies, branded generic firms and biotechnology groups. INyX manufactures for a majority of global markets, including North America, Europe, Latin America and the Middle East.
Our company’s R&D and production operations are conducted through a wholly owned subsidiary, INyX Pharma Limited, which has a 60,000 square foot manufacturing facility and a 15,000 square foot laboratory site in Runcorn, UK. These facilities are ISO 9001 accredited and are cGMP (current Good Manufacturing Practice) compliant with the United States Food and Drug Administration (FDA) and the Canadian and European regulatory bodies. INyX is one of only three independent pharmaceutical companies to have FDA, Canadian and European regulatory approval for pharmaceutical aerosol production.
We have a total of approximately 140 employees, the majority of whom are at INyX Pharma in the UK. The corporate headquarters of INyX, Inc., the parent company, is in New York City.
In 2004, the next phase of INyX's evolution will commence, which is to leverage the company's aerosol drug delivery technology to develop our own proprietary products. We plan to start marketing our own products in the fourth quarter of 2004. We already have strategic relationships in place with key clients for business-development support and intend to use their pharmaceutical sales forces to market INyX proprietary products in the dermatology, respiratory and allergy markets.
Products and services
INyX, Inc.’s wholly owned subsidiary, INyX Pharma, is a developer and manufacturer of niche pharmaceutical products primarily in the respiratory, allergy, dermatological and topical areas.
INyX’s development operation is vertically integrated into the manufacturing operation, thereby allowing the company to provide complementary scale-up and commercialisation services for our contract manufacturing clients.
INyX Pharma’s development operation is comprised of a 15-person pharmaceutical research and development group located at a 15,000 square foot laboratory and a 15,000 square foot office complex at Manor Park, Runcorn, UK.
Operating from well-equipped facilities near to our manufacturing division in Runcorn, our development facility offers a spectrum of pharmaceutical formulation services.
- Formulation services
- Analytical development and validation
- Stability services
- Regulatory support
- Integrated project management
Presently, five types of pharmaceutical products are manufactured at our 60,000-square foot production facility located at Astmoor, Runcorn, UK.
- Hydrocarbon aerosols
- Metered dose inhalers (MDIs) (CFC & HFA)
- Dry powder inhalers (DPIs)
- Metered dose pump spray
- Saline aerosols
Specific expertise has been developed in the above products as well as investment in automated filling and assembly equipment for cost-effective production.
Clients receive identification, selection or development of the most appropriate drug delivery systems, with access to the most technically advanced valves, cans and containers on the world market. A comprehensive range of pharmaceutical manufacturing, filling and packaging services, with a sophisticated QA system rigorously maintained to ensure consistent quality, are offered. Any combination of these services is available, customised to the client's specifications.
Our production facility is approved by the UK Medicines Agency (MHRA), the US FDA, Canadian TPD and has received ISO 9001 accreditation.
For more information, please visit our web site: